Emmaus Life Sciences Inc, a company involved in sickle cell disease treatment, announced yesterday that it has named Michael Schwarz as its new product manager for Endari.
Schwarz has more than 15 years of experience in the commercialisation of specialty medicines and other therapies for treating rare diseases. He has played an integral part in establishing sales process infrastructure and contributed in key leadership roles in the launches and commercial expansion of international brand medicines. He joins Emmaus from Novartis Pharmaceuticals, where he helped lead the implementation of Car-T therapy for haematological malignancies and was responsible for supporting haematology, HIV and HBV franchises.
Yutaka Niihara, MD, MPH, chairman and chief executive officer of Emmaus, said, 'We are very pleased to have Mike join us. His proven commercialisation talents and experience in the pharmaceutical industry will bring new and complementary skill sets to Emmaus as we continue to expand in the sickle cell disease sector along with developments in new areas.'
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer